Lifetime Overproduction of Circulating Angiotensin-(1-7) Attenuates Deoxycorticosterone Acetate-Salt Hypertension-Induced Cardiac Dysfunction and Remodeling
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2010
|
Resumo |
We evaluated the development of arterial hypertension, cardiac function, and collagen deposition, as well as the level of components of the renin-angiotensin system in the heart of transgenic rats that overexpress an angiotensin (Ang)-(1-7)-producing fusion protein, TGR(A1-7)3292 (TG), which induces a lifetime increase in circulating levels of this peptide. After 30 days of the induction of the deoxycorticosterone acetate (DOCA)-salt hypertension model, DOCA-TG rats were hypertensive but presented a lower systolic arterial pressure in comparison with DOCA-Sprague-Dawley (SD) rats. In contrast to DOCA-SD rats that presented left ventricle (LV) hypertrophy and diastolic dysfunction, DOCA-TG rats did not develop cardiac hypertrophy or changes in ventricular function. In addition, DOCA-TG rats showed attenuation in mRNA expression for collagen type I and III compared with the increased levels of DOCA-SD rats. Ang II plasma and LV levels were reduced in SD and TG hypertensive rats in comparison with normotensive animals. DOCA-TG rats presented a reduction in plasma Ang-(1-7) levels; however, there was a great increase in Ang-(1-7) (approximate to 3-fold) accompanied by a decrease in mRNA expression of both angiotensin-converting enzyme and angiotensin-converting enzyme 2 in the LV. The mRNA expression of Mas and Ang II type 1 receptors in the LV was not significantly changed in DOCA-SD or DOCA-TG rats. This study showed that TG rats with increased circulating levels of Ang-(1-7) are protected against cardiac dysfunction and fibrosis and also present an attenuated increase in blood pressure after DOCA-salt hypertension. In addition, DOCA-TG rats showed an important local increase in Ang-(1-7) levels in the LV, which might have contributed to the attenuation of cardiac dysfunction and prefibrotic lesions. (Hypertension. 2010;55:889-896.) CAPES Coordenacao de Aperfeicoamentode Pessoal de Nivel Superior High Blood Pressure Council CNPq Conselho Nacional de Desenvolvimento Cientifico e Tecnologico Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) CAPES Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Programa de Nucleos de Excelencia (PRONEX) Instituto Nacional de Ciencia e Tecnologia (INCT) |
Identificador |
HYPERTENSION, v.55, n.4, p.889-U134, 2010 0194-911X http://producao.usp.br/handle/BDPI/27214 10.1161/HYPERTENSIONAHA.110.149815 |
Idioma(s) |
eng |
Publicador |
LIPPINCOTT WILLIAMS & WILKINS |
Relação |
Hypertension |
Direitos |
restrictedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
Palavras-Chave | #angiotensin-(1-7) #cardiac remodeling #cardiac function #hypertension #FUSION PROTEIN #RECEPTOR MAS #MYOCARDIAL-INFARCTION #CONVERTING ENZYME-2 #MARKED CHANGES #HEART FUNCTION #II RECEPTORS #RATS #HYPERTROPHY #MICE #Peripheral Vascular Disease |
Tipo |
article original article publishedVersion |